Recently, the implementation of TTF in glioblastoma treatment was associated with the downregulation of breast cancer type 1 susceptibility protein (BRCA1) signaling and the reduction in DNA double-strand break repair capacity [234]. The gene discussed is BRCA1; the disease is glioblastoma.